Share Twitter LinkedIn Facebook Email Jean-Marie Michot, MD Drug Development Department Gustave Roussy, France jean-marie.michot@gustaveroussy.fr discusses IO toxicities in Kidney Cancer at the Kidney Cancer Association International Symposium 2019 in Dubrovnik, Croatia
Tivozanib for RCC: Unpacking Efficacy, Safety, and Dose Optimization – Bradley McGregor, MD – Dana Farber Genitourinary 3 Mins Read
Renal Cell Carcinoma TiNivo-2 Study: Patient-Reported Outcomes in Treatment Post-ICI Kidney 3 Mins Read
VIDEO: FDA Approves Atezolizumab / Tecentriq Hybreza For Subcutaneous PD-(L)1 Cancer Immunotherapy in NSCLC Kidney 4 Mins Read